Literature DB >> 24676554

STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.

Xuan Zhou1, Yu Ren2, Aiqin Liu3, Lei Han4, Kailiang Zhang4, Shasha Li3, Peng Li5, Ping Li3, Chunsheng Kang4, Xudong Wang6, Lun Zhang3.   

Abstract

Abnormalities in signal transducer and activator of transcription 3 (STAT3) are involved in the oncogenesis of oral squamous cell carcinoma (OSCC). MicroRNA-21 (miR-21) is an important gene expression regulator to OSCC. miR-21 induction by STAT3 has been reported in multiple human cancers. In the present study, we found that STAT3 (-/p) expression was positively correlated with miR-21 in 60 OSCC samples. A reporter gene assay showed that miR-21 overexpression was dependent on STAT3 activation. WP1066, a small molecular inhibitor of STAT3, was used to suppress STAT3 expression in OSCC cells. TSCCA and TCA8113 showed reduction in tumor cell proliferation, invasion ability and miR-21 expression by WP1066 treatment. In addition, the expression of miR-21 target proteins [programmed cell death 4 (PDCD4), tissue inhibitor of metalloproteinase 3 (TIMP-3) and phosphatase and tensin homolog (PTEN)] was upregulated. Restored STAT3 expression by IL-6 induced miR-21 overexpression, which further confirmed the correlation between STAT3 and miR-21. WP1066 inhibited tumor growth and induced tumor cell apoptosis in the TSCCA xenograft tumor model. Western blotting and immunohistochemistry staining indicated that STAT3 (-/p), Ki67, Bcl-2 and MMP-2 expressions decreased in the WP1066-treated group; PDCD4, TIMP-3 and PTEN expression increased simulta-neously. The present study provides evidence that targeting STAT3 could regulate OSCC cell growth in a miR-21-dependent manner and WP1066 could be a novel candidate drug to treat OSCC by inhibiting STAT3/miR-21 axis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676554     DOI: 10.3892/or.2014.3114

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  34 in total

Review 1.  MicroRNAs as effective surrogate biomarkers for early diagnosis of oral cancer.

Authors:  Min Cao; Lijuan Zheng; Jianzhou Liu; Thomas Dobleman; Shen Hu; Vay Liang W Go; Ge Gao; Gary Guishan Xiao
Journal:  Clin Oral Investig       Date:  2018-01-03       Impact factor: 3.573

2.  MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway.

Authors:  Youzhong Ren; Hongguang Zhu; Chunyuan Chi; Fanghong Yang; Xin Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  The interplay of cytokine signaling and non-coding RNAs in head and neck squamous cell carcinoma pathobiology.

Authors:  Vivek Sharma
Journal:  Mol Biol Rep       Date:  2022-07-24       Impact factor: 2.742

Review 4.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

5.  Hematoporphyrin monomethyl ether mediated photodynamic therapy inhibits oral squamous cell carcinoma by regulating the P53-miR-21-PDCD4 axis via singlet oxygen.

Authors:  Peisong Meng; Yi Sun; Enze Li; Yunqing Liu; Cuiping Wang; Liping Song
Journal:  Lasers Med Sci       Date:  2022-03-09       Impact factor: 2.555

6.  Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis.

Authors:  Fu Sang Luk; Roy Y Kim; Kang Li; Daniel Ching; David K Wong; Sunil K Joshi; Isabella Imhof; Norman Honbo; Holly Hoover; Bo-Qing Zhu; David H Lovett; Joel S Karliner; Robert L Raffai
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

7.  Physcion 8-O-β-glucopyranoside induces mitochondria-dependent apoptosis of human oral squamous cell carcinoma cells via suppressing survivin expression.

Authors:  Meng-Dong Liu; Shi-Jiang Xiong; Fei Tan; Yi Liu
Journal:  Acta Pharmacol Sin       Date:  2016-04-11       Impact factor: 6.150

8.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

9.  A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma.

Authors:  Sakthi Lenin; Elise Ponthier; Kaitlin G Scheer; Erica C F Yeo; Melinda N Tea; Lisa M Ebert; Mariana Oksdath Mansilla; Santosh Poonnoose; Ulrich Baumgartner; Bryan W Day; Rebecca J Ormsby; Stuart M Pitson; Guillermo A Gomez
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 10.  Regulation and involvement of matrix metalloproteinases in vascular diseases.

Authors:  Matthew Amin; Sathnur Pushpakumar; Nino Muradashvili; Sourav Kundu; Suresh C Tyagi; Utpal Sen
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.